An upcoming question based-review system for drug master files as well as a draft guidance with new procedures for reviewing DMFs called “completeness assessments” are expected to improve the quality of DMFs submitted to FDA with respect to drug substance development.
Aloka Srinivasan, a principal consultant with Parexel, formerly a team leader with FDA’s Office of Generic Drugs, described some of the deficiencies she used to see in DMFs when she...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?